NCT01860937View on ClinicalTrials.gov

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Relapsed B-Cell Acute Lymphoblastic Leukemia
Interventions
PROCEDURE

leukapheresis or collection of PBMCs

DRUG

cyclophosphamide based chemotherapy regimens

BIOLOGICAL

modified T cells

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

02115

Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital, Boston

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01860937 - T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter